Shire Emphasizes The GI Space In Its Bid For Movetis

Only five years ago, Shire's specialty pharma business consisted of one product, Adderall XR, one market, the U.S., and one patient type - children. Multiple generics companies had filed ANDAs, however, and the company was looking to broaden its base

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet